Unique technology, Unique market
Xspray Pharma’s unique technology could improve the quality of life, and make it possible for more patients to access improved Protein Kinase Inhibitor (PKI) drugs for treatment of cancer.
Link to Capital Markets day, May 2022.
-
Latest report
Interim Report Q1 2022 -
Subscribe
Get our latest press releases and reports

Press releases
Regulatory press release 2022-06-17
Dasynoc granted Orphan Drug Designation in the US for the treatment of chronic myeloid leukemia
Regulatory press release 2022-06-15
Xspray Pharma appoints Thomas Walz as Chief Medical Officer
Press release 2022-06-09
Xspray Pharma’s long-term incentive program LTI 2022 fully subscribed
Regulatory press release 2022-05-19
Bulletin from the 2022 Annual General Meeting of Xspray Pharma AB (publ)
Press release 2022-05-06
Xspray Pharma – Capital Markets Day Invitation

Xspray Pharma uses its innovative, patented technology to develop amorphous product candidates that are improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Often the original companies have secondary patents that are based on the crystalline forms of the active substance. Since Xspray Pharma’s products are amorphous, they can be marketed as soon as the original companies’ drug substance patents expire. This is a unique opportunity for a favorable market establishment on a multi billion dollar market.

We see a large potential for our product portfolio. Our technology is compatible for most of the 72 US markeded protein kinase inhibitors. The company’s new porduct candidates are being developed in the same manner as the company´s initial product, Dasynoc. The process is reproducible and reduces the effective developing time for future products in our pipeline. This is an exciting time! Per Andersson, CEO